Last update
3/8/2026
Reviewed By
Overview
SCIENTIFIC SCORE
Questionable
Based on 6 Researches
6.3
USERS' SCORE
Good
Based on 8 Reviews
8.1
Supplement Facts
Serving Size: 1 Veg Capsule
Amount Per Serving
%DV
Vitamin K2 (as Menaquinone-4) (MK-4)
100 mcg
**
Alfalfa Powder (Aerial Parts)
250 mg
**
Top Medical Research Studies
9
Vitamin K1 reduces coronary calcifications
We aimed to determine how vitamin K1 affects coronary artery calcifications in patients undergoing hemodialysis. In our study with 60 participants, we compared the effects of intravenous vitamin K1 against a placebo over 12 months.
The results showed that vitamin K1 significantly slowed the progression of coronary artery calcifications by 55%, compared to the placebo group. This finding suggests vitamin K1 may offer an important benefit in managing heart health for those with chronic kidney disease.
The results showed that vitamin K1 significantly slowed the progression of coronary artery calcifications by 55%, compared to the placebo group. This finding suggests vitamin K1 may offer an important benefit in managing heart health for those with chronic kidney disease.
Read More
7
Real-world effectiveness of blood thinners
We explored how well the outcomes of landmark trials for two blood thinners—apixaban and rivaroxaban—hold up in real-world atrial fibrillation (AF) patients. By examining data from the GARFIELD-AF registry, we found that patients on these treatments had similar results in preventing strokes, bleeding, and overall mortality when compared to those on vitamin K antagonists.
While apixaban showed promising results, rivaroxaban had more mixed findings, yet overall, the effectiveness and safety were largely in line with the original trials. This suggests that these medications can be appropriately used in everyday medical practice.
While apixaban showed promising results, rivaroxaban had more mixed findings, yet overall, the effectiveness and safety were largely in line with the original trials. This suggests that these medications can be appropriately used in everyday medical practice.
Read More
4
Vitamin K antagonists raise mortality risk
We analyzed data from a study involving patients who underwent mitral valve repair and had atrial fibrillation, comparing the effects of direct oral anticoagulants to vitamin K antagonists (VKAs).
Surprisingly, we found that both treatments led to similar rates of serious complications, like strokes or bleeding. However, those on VKAs showed a significantly higher overall mortality. This suggests that while both anticoagulants may work similarly for immediate outcomes, VKAs might come with increased risks for longer-term survival. Further research is needed to clarify the best options for these patients.
Surprisingly, we found that both treatments led to similar rates of serious complications, like strokes or bleeding. However, those on VKAs showed a significantly higher overall mortality. This suggests that while both anticoagulants may work similarly for immediate outcomes, VKAs might come with increased risks for longer-term survival. Further research is needed to clarify the best options for these patients.
Read More
Most Useful Reviews
9
Reduced artery plaque
44 people found this helpful
It has worked wonders for my dental health. After my heart attack in February 2018, I followed an aggressive plant-based diet alongside taking this product with vitamin D3. A recent calcium scoring CT scan revealed that the plaque in my left artery has decreased from severe to moderate, and the other arteries show no plaque. I'm truly grateful for this outcome, as it significantly aids in treating heart disease.
Read More
0
Negative side effects
3 people found this helpful
I experienced heart palpitations and dizziness after using this. I felt quite ill.
Read More
9
Doctor-recommended
2 people found this helpful
As per my doctor's prescription, I take K2 to aid D3 absorption. It is indispensable for the heart and blood vessels, and I've noticed significant benefits. The tablets are easy to swallow and the quality is good.
Read More
Medical Researches
SCIENTIFIC SCORE
Questionable
Based on 6 Researches
6.3
- All Researches
9
Vitamin K1 reduces coronary calcifications
We aimed to determine how vitamin K1 affects coronary artery calcifications in patients undergoing hemodialysis. In our study with 60 participants, we compared the effects of intravenous vitamin K1 against a placebo over 12 months.
The results showed that vitamin K1 significantly slowed the progression of coronary artery calcifications by 55%, compared to the placebo group. This finding suggests vitamin K1 may offer an important benefit in managing heart health for those with chronic kidney disease.
The results showed that vitamin K1 significantly slowed the progression of coronary artery calcifications by 55%, compared to the placebo group. This finding suggests vitamin K1 may offer an important benefit in managing heart health for those with chronic kidney disease.
Read More
9
We analyzed a study comparing two anticoagulation options—direct oral anticoagulants (DOACs) and vitamin K antagonists (VKAs)—in patients with non-valvular atrial fibrillation who faced blood clots despite previous treatment.
Our findings reveal that those on DOACs had significantly fewer cardioembolic events and complications following left atrial appendage closure.
In contrast, patients on VKAs did not show the same benefit, which suggests that DOACs may be a more effective option for ongoing treatment in these cases.
Our findings reveal that those on DOACs had significantly fewer cardioembolic events and complications following left atrial appendage closure.
In contrast, patients on VKAs did not show the same benefit, which suggests that DOACs may be a more effective option for ongoing treatment in these cases.
Read More
7
Real-world effectiveness of blood thinners
We explored how well the outcomes of landmark trials for two blood thinners—apixaban and rivaroxaban—hold up in real-world atrial fibrillation (AF) patients. By examining data from the GARFIELD-AF registry, we found that patients on these treatments had similar results in preventing strokes, bleeding, and overall mortality when compared to those on vitamin K antagonists.
While apixaban showed promising results, rivaroxaban had more mixed findings, yet overall, the effectiveness and safety were largely in line with the original trials. This suggests that these medications can be appropriately used in everyday medical practice.
While apixaban showed promising results, rivaroxaban had more mixed findings, yet overall, the effectiveness and safety were largely in line with the original trials. This suggests that these medications can be appropriately used in everyday medical practice.
Read More
5
Vitamin K antagonists: outcomes assessed
We investigated the impact of vitamin K antagonists (VKA) on patients with atrial fibrillation (AF). Our study included 1,350 patients who received VKA for at least a year, tracking various outcomes like cardiovascular death and thromboembolic events.
Interestingly, while we noted predictors for these clinical outcomes—like previous thromboembolism or bleeding—no significant improvement in heart disease was directly linked to vitamin K treatment itself. Instead, factors such as age and kidney function played crucial roles in determining patient outcomes.
Interestingly, while we noted predictors for these clinical outcomes—like previous thromboembolism or bleeding—no significant improvement in heart disease was directly linked to vitamin K treatment itself. Instead, factors such as age and kidney function played crucial roles in determining patient outcomes.
Read More
4
Vitamin K antagonists raise mortality risk
We analyzed data from a study involving patients who underwent mitral valve repair and had atrial fibrillation, comparing the effects of direct oral anticoagulants to vitamin K antagonists (VKAs).
Surprisingly, we found that both treatments led to similar rates of serious complications, like strokes or bleeding. However, those on VKAs showed a significantly higher overall mortality. This suggests that while both anticoagulants may work similarly for immediate outcomes, VKAs might come with increased risks for longer-term survival. Further research is needed to clarify the best options for these patients.
Surprisingly, we found that both treatments led to similar rates of serious complications, like strokes or bleeding. However, those on VKAs showed a significantly higher overall mortality. This suggests that while both anticoagulants may work similarly for immediate outcomes, VKAs might come with increased risks for longer-term survival. Further research is needed to clarify the best options for these patients.
Read More
User Reviews
USERS' SCORE
Good
Based on 8 Reviews
8.1
- All Reviews
- Positive Reviews
- Negative Reviews
9
Reduced artery plaque
44 people found this helpful
It has worked wonders for my dental health. After my heart attack in February 2018, I followed an aggressive plant-based diet alongside taking this product with vitamin D3. A recent calcium scoring CT scan revealed that the plaque in my left artery has decreased from severe to moderate, and the other arteries show no plaque. I'm truly grateful for this outcome, as it significantly aids in treating heart disease.
Read More
0
Negative side effects
3 people found this helpful
I experienced heart palpitations and dizziness after using this. I felt quite ill.
Read More
9
Doctor-recommended
2 people found this helpful
As per my doctor's prescription, I take K2 to aid D3 absorption. It is indispensable for the heart and blood vessels, and I've noticed significant benefits. The tablets are easy to swallow and the quality is good.
Read More
9
Improves heart health
K-2 has worked well for me. I've used it for some time for heel spurs and heart health, finding it to be an excellent product.
Read More
7.5
Prevents caries
3 people found this helpful
I purchased this on my dentist's advice to prevent caries while taking vitamin D3. K2 is important as our bodies produce insufficient amounts, and it is beneficial for preventing heart disease. I've had no side effects and will keep ordering it.
Read More
Frequently Asked Questions
9
Reduced artery plaque
44 people found this helpful
It has worked wonders for my dental health. After my heart attack in February 2018, I followed an aggressive plant-based diet alongside taking this product with vitamin D3. A recent calcium scoring CT scan revealed that the plaque in my left artery has decreased from severe to moderate, and the other arteries show no plaque. I'm truly grateful for this outcome, as it significantly aids in treating heart disease.
0
Negative side effects
3 people found this helpful
I experienced heart palpitations and dizziness after using this. I felt quite ill.
9
Doctor-recommended
2 people found this helpful
As per my doctor's prescription, I take K2 to aid D3 absorption. It is indispensable for the heart and blood vessels, and I've noticed significant benefits. The tablets are easy to swallow and the quality is good.
5
Vitamin K antagonists: outcomes assessed
We investigated the impact of vitamin K antagonists (VKA) on patients with atrial fibrillation (AF). Our study included 1,350 patients who received VKA for at least a year, tracking various outcomes like cardiovascular death and thromboembolic events.
Interestingly, while we noted predictors for these clinical outcomes—like previous thromboembolism or bleeding—no significant improvement in heart disease was directly linked to vitamin K treatment itself. Instead, factors such as age and kidney function played crucial roles in determining patient outcomes.
Interestingly, while we noted predictors for these clinical outcomes—like previous thromboembolism or bleeding—no significant improvement in heart disease was directly linked to vitamin K treatment itself. Instead, factors such as age and kidney function played crucial roles in determining patient outcomes.
4
Vitamin K antagonists raise mortality risk
We analyzed data from a study involving patients who underwent mitral valve repair and had atrial fibrillation, comparing the effects of direct oral anticoagulants to vitamin K antagonists (VKAs).
Surprisingly, we found that both treatments led to similar rates of serious complications, like strokes or bleeding. However, those on VKAs showed a significantly higher overall mortality. This suggests that while both anticoagulants may work similarly for immediate outcomes, VKAs might come with increased risks for longer-term survival. Further research is needed to clarify the best options for these patients.
Surprisingly, we found that both treatments led to similar rates of serious complications, like strokes or bleeding. However, those on VKAs showed a significantly higher overall mortality. This suggests that while both anticoagulants may work similarly for immediate outcomes, VKAs might come with increased risks for longer-term survival. Further research is needed to clarify the best options for these patients.
9
Vitamin K1 reduces coronary calcifications
We aimed to determine how vitamin K1 affects coronary artery calcifications in patients undergoing hemodialysis. In our study with 60 participants, we compared the effects of intravenous vitamin K1 against a placebo over 12 months.
The results showed that vitamin K1 significantly slowed the progression of coronary artery calcifications by 55%, compared to the placebo group. This finding suggests vitamin K1 may offer an important benefit in managing heart health for those with chronic kidney disease.
The results showed that vitamin K1 significantly slowed the progression of coronary artery calcifications by 55%, compared to the placebo group. This finding suggests vitamin K1 may offer an important benefit in managing heart health for those with chronic kidney disease.
9
We analyzed a study comparing two anticoagulation options—direct oral anticoagulants (DOACs) and vitamin K antagonists (VKAs)—in patients with non-valvular atrial fibrillation who faced blood clots despite previous treatment.
Our findings reveal that those on DOACs had significantly fewer cardioembolic events and complications following left atrial appendage closure.
In contrast, patients on VKAs did not show the same benefit, which suggests that DOACs may be a more effective option for ongoing treatment in these cases.
Our findings reveal that those on DOACs had significantly fewer cardioembolic events and complications following left atrial appendage closure.
In contrast, patients on VKAs did not show the same benefit, which suggests that DOACs may be a more effective option for ongoing treatment in these cases.
References
- Liporace IL, Oliveira GBF, Alves LBO, Galassi NM, Jeronimo AD, et al. Incidence and Predictors of Clinical Outcomes in Patients with Valvular and Nonvalvular Atrial Fibrillation Using Vitamin K Antagonists. Arq Bras Cardiol. 2025;122:e20240147. 10.36660/abc.20240147
- Schipper JH, Sommer AS, Nies RJ, Metze C, Meertens MM, et al. Direct Oral Anticoagulants Versus Vitamin K Antagonists After Mitral Valve Transcatheter Edge-to-Edge Repair in Patients With Atrial Fibrillation: A Single-Center Observational Study. J Am Heart Assoc. 2025;14:e038834. 10.1161/JAHA.124.038834
- Babadagli HE, Ye J, Chen J, Turgeon R, Wang EH. Efficacy and safety of anti-thrombotic therapy after surgical mitral valve repair: a scoping review. Open Heart. 2025;12. 10.1136/openhrt-2024-003158
- Himmelreich JCL, Virdone S, Camm AJ, Pieper K, Harskamp RE, et al. Emulation of ARISTOTLE and ROCKET AF trials in real-world atrial fibrillation patients results in similar efficacy and safety as original landmark trials: insights from the GARFIELD-AF registry. Open Heart. 2025;12. 10.1136/openhrt-2024-002966
- Macias-Cervantes HE, Ocampo-Apolonio MA, Guardado-Mendoza R, Baron-Manzo M, Pereyra-Nobara TA, et al. Effect of vitamin K1 supplementation on coronary calcifications in hemodialysis patients: a randomized controlled trial. J Nephrol. 2025;38:511. 10.1007/s40620-024-02154-9
- Preda A, Falasconi G, Melillo F, Margonato D, Posteraro GA, et al. Left atrial appendage closure in patients with failure of anticoagulation therapy: A multicenter comparative study on the hybrid strategy using DOACs and VKAs. Int J Cardiol. 2025;421:132875. 10.1016/j.ijcard.2024.132875
Data last updated:
